Curcuminoids Exert Glucose-lowering Effect In Type 2 Diabetes By Decreasing Serum Free Fatty Acids: A Double-blind, Placebo-controlled Trial
Notes for this study:
||(ug/mL). Placebo: before 2484.4 ± 392.7, after 2393.2 ± 378.1. Curcuminoid: before 2494.8 ± 268.9, after 2104.8 ± 248.3
|Number of Subjects
||18-29, 30-44, 45-64, 65+
In a randomized, double-blind, placebo-controlled trial, 109 overweight/obese participants with type 2 diabetes were assigned to take 300 mg of a curcuminoid extract (97.49% purity, curcumin 36.06%, demethoxycurcumin, 18.85%, bisdemethoxycurcumin, 42.58%) or placebo daily for 3 months.
The results were adjusted for age, gender, smoking history, lipid-lowering drugs, physical activity level, blood pressure, diabetes duration, and drug treatment. The curcuminoid group saw a notable, statistically significant reduction compared with the placebo group fasting glucose, HbA1c, insulin resistance, serum free fatty acids, lipoprotein lipase activity, and triglycerides. The change compared with placebo for total cholesterol, LDL-C, HDL-C, Apo A-I, and Apo B, was not statistically significant.
There were also no notable, statistically significant differences for red blood cell count, white blood cells, hemoglobin, total protein in serum, albumin, urea nitrogen, creatinine, ALT and AST.